AI-generated analysis, not investment advice. The articles are written by AI, edited, and checked against company filings — but the judgements are opinions and the figures go stale. How this is made · Terms

Gilead Sciences (GILD) valuation, revenue & earnings

P/E and P/S history, revenue and growth, ROIC vs. cost of capital, segments, earnings and analyst forecasts

At a glance
Market capitalisation$179B
Moat ratingNarrow moat
ValuationFair
Revenue, and where it comes from$29.44bn in 2025: HIV $20.75bn (70.5%), Oncology $3.24bn, Liver Disease $3.22bn, Veklury $0.91bn, Other $0.80bn, royalties $0.53bn; Biktarvy alone $14.33bn (48.7%); United States 72% of product sales

Recent years are exact, taken from company filings; the earliest years are approximate. Forecast figures are Wall Street consensus, not company guidance. Read the full Gilead Sciences moat analysis →